Quarterly ResultMay 6, 2026, 04:23 PM
electroCore Q1 Net Sales +43% to $9.6M; Adjusted EBITDA Loss Improves 24%
AI Summary
electroCore reported record first quarter 2026 net sales of $9.6 million, a 43% increase year-over-year, driven by strong growth in U.S. prescription sales and Truvaga. The company's GAAP net loss increased to $5.3 million, primarily due to one-time leadership transition expenses, but Adjusted EBITDA net loss improved by 24% to $2.3 million. electroCore reaffirmed its full-year 2026 revenue guidance of approximately 30% annual growth. Michael Fox also joined as Chief Operating Officer in April 2026.
Key Highlights
- Net sales increased 43% year-over-year to a record $9.6 million in Q1 2026.
- GAAP net loss was $5.3 million in Q1 2026, compared to $3.9 million in Q1 2025.
- Adjusted EBITDA net loss improved 24% year-over-year to $2.3 million.
- Gross margin expanded to 87% in Q1 2026, up from 85% in the prior year.
- U.S. prescription gammaCore revenue grew approximately 26% year-over-year.
- Truvaga revenue grew approximately 38% year-over-year to $1.5 million.
- Reaffirmed full-year 2026 revenue guidance of approximately 30% annual growth.
- Cash, cash equivalents, and marketable securities totaled $8.8 million as of March 31, 2026.